Selank is a synthetic heptapeptide anxiolytic nootropic developed at the Institute of Molecular Genetics, Russian Academy of Sciences — the same laboratory that created Semax. It is derived from the endogenous tetrapeptide tuftsin (an immunomodulatory peptide fragment of IgG) with the addition of a stabilizing Pro-Gly-Pro C-terminal sequence. Selank is approved in Russia for the treatment of generalized anxiety disorder (GAD) and as a nootropic. Its anxiolytic effects are comparable to benzodiazepines but without sedation, cognitive impairment, or addiction potential. It also enhances cognitive function, modulates serotonin metabolism, and has immunostimulatory properties.
Harm Reduction
Selank is administered intranasally, typically as a 0.15% solution. Standard dosing is 250-750 mcg per day divided into 2-3 administrations. Start with the lowest dose. For the N-Acetyl Selank Amidate...
Read full harm reduction guide